Sanofi’s Post

View organization page for Sanofi, graphic

4,193,859 followers

FDA has granted Fast Track designation for our two combination vaccine candidates to prevent #influenza and #COVID19 infections. Both vaccine candidates combine two already licensed standalone vaccines with proven efficacy. This Fast Track designation recognizes the potential for our combination vaccine candidates to address the significant burden of influenza and COVID-19 on individuals and healthcare systems. Read our press release: http://spkl.io/6042fwVh8

  • No alternative text description for this image

Congratulations Sanofi! You are always making a difference in people's lives.

Like
Reply
KOSISOCHUKWU CHRISTIANA

A Pharmacist open to incredible networking and affectionate towards innovations, a public speaker, highly passionate about impactful leadership. Open to learning, improvement and development.

1w

This is a huge feat. Congratulations 🎉!

Like
Reply
Lisa King, BCMAS, CCRP, PhD

Director of Clinical Research | Expert in Clinical Trial Management, Regulatory Compliance & Business Development | Driving Operational Excellence & Advancing Medical Affairs | Ph.D., CCRP, BC-MAS, AI Certified

1w

Congratulations on achieving Fast Track designation for your combination vaccine candidates! This is a significant milestone that underscores the innovative approach your team is taking to streamline and enhance immunization efforts. Combining vaccines not only simplifies the vaccination process but also has the potential to improve compliance and coverage rates. Looking forward to seeing the positive impact this will have on public health and the efficiency of healthcare delivery. Keep up the great work!

Like
Reply

Congrats to Sanofi on the Fast Track designation. At VR Print, we're proud to support the pharma industry with high-quality labelling solutions.

Like
Reply
Mike Parshenkov

Digital Manager | Founder of AxonScience | Researcher in Drug Development & Clinical Trials | Exploring Pharmaceutical Innovations

1w

Fantastic news, Sanofi 💜 The Fast Track designation highlights the incredible innovation happening in vaccine development. I’m sure that the following combining influenza and COVID-19 prevention into a single solution is a significant step forward in addressing public health challenges efficiently👏. Kudos to the team driving this impactful work—looking forward to seeing its progress and contribution to global healthcare! I’m glad to be member of our company🥳

Assure your compliance training and LMS is all set up as this great achievement is out there 💪🏼🤓

Like
Reply
Haiyue Xu

Scientific consultant in TFF Pharmaceuticals & Postdoctoral Research Fellow at The University of Texas at Austin

1w

If approved by the FDA, a new vaccine adjuvant, Matrix M, will enter the market. It is derived from saponin and features a honeycomb-like structure approximately 40 nm in size. Any thoughts on APIs formulated with or conjugated onto it?

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics